In a filing, Cassava Sciences Inc revealed its Chief Medical Officer Kupiec James William unloaded Company’s shares for reported $15480.0 on Nov 29 ’24. In the deal valued at $3.87 per share,4,000 shares were sold. As a result of this transaction, Kupiec James William now holds 0 shares worth roughly $0.0.
Then, Schoen Eric sold 59,800 shares, generating $230,828 in total proceeds. Upon selling the shares at $3.86, the Chief Financial Officer now owns 11,500 shares.
Before that, Schoen Eric sold 2,000 shares. Cassava Sciences Inc shares valued at $7,640 were divested by the Chief Financial Officer at a price of $3.82 per share. As a result of the transaction, Schoen Eric now holds 0 shares, worth roughly $0.0.
H.C. Wainwright downgraded its Cassava Sciences Inc [SAVA] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in early October from “a Neutral” to “a Buy”. H.C. Wainwright also remained covering SAVA and has decreased its forecast on July 01, 2024 with a “Neutral” recommendation from previously “Buy” rating. B. Riley Securities revised its rating on November 16, 2022. It rated SAVA as “a Neutral” which previously was an “a Buy”.
Price Performance Review of SAVA
On Monday, Cassava Sciences Inc [NASDAQ:SAVA] saw its stock fall -0.96% to $2.07. Over the last five days, the stock has gained 13.11%. Cassava Sciences Inc shares have fallen nearly -12.29% since the year began. Nevertheless, the stocks have fallen -91.00% over the past one year.
How much short interest is there in Cassava Sciences Inc?
A steep rise in short interest was recorded in Cassava Sciences Inc stocks on 2025-04-30, dropping by -1.12 million shares to a total of 10.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 11.15 million shares. There was a decline of -11.15%, which implies that there is a negative sentiment for the stock.
